Key Takeaways
- The global nuclear medicine market is projected to grow from ~$7.8 billion in 2024 to over $30.7 billion by 2034, driven by theranostics, precision diagnostics, and expanded radiopharmaceutical access.
- GE HealthCare will showcase AI‑enabled workflows, imaging platforms, and radiopharmaceuticals at the 2026 SNMMI annual meeting to support scaling of precision care.
- Cardiology innovations (Flyrcado PET MPI) aim to bring myocardial perfusion imaging to community and mobile settings.
- Neurology solutions (Vizamyl, MIMneuro) facilitate routine amyloid PET interpretation for Alzheimer’s work‑up.
- Oncology tools (StarGuide SPECT/CT, iRT, MIM portfolio) streamline whole‑body tumor burden quantification and theranostic treatment planning.
- Adaptive Theranostics integrates molecular imaging, quantitative analytics, and multidisciplinary workflows to personalize radioligand therapy over time.
- Real‑world impact highlights include MIM KineticID (dynamic PET kinetic modeling), MIM LesionID Pro (AI‑driven whole‑body tumor analysis), Omni Legend PET/CT, StarGuide SPECT/CT, and MINItrace Magnix compact cyclotron for on‑site tracer production.
- GE HealthCare emphasizes building an end‑to‑end ecosystem—from tracer manufacturing to workflow integration—to move precision nuclear medicine from promise to everyday practice.
Overview
On June 1, 2026, GE HealthCare announced its participation in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, where it will unveil a suite of next‑generation technologies and AI‑enabled workflows. The announcement coincides with rapid expansion in nuclear medicine, fueled by growing adoption of theranostics, broader radiopharmaceutical availability, and increased investment in precision diagnostics and targeted therapies. Market forecasts anticipate the sector swelling from roughly $7.8 billion in 2024 to more than $30.7 billion by 2034, reflecting a compound annual growth rate that underscores the urgency for scalable, efficient solutions. GE HealthCare’s presentation aims to demonstrate how its portfolio can help health systems meet rising demand while improving access, operational efficiency, and clinical confidence.
Market Expansion and Drivers
The surge in nuclear medicine activity is rooted in several converging trends. First, the rising prevalence of chronic diseases—cardiovascular disorders, neurodegenerative conditions, and cancer—creates a pressing need for early, accurate detection and personalized treatment pathways. Second, advances in radiopharmaceutical chemistry enable novel PET and SPECT tracers that target specific biological processes, thereby expanding the diagnostic and therapeutic repertoire. Third, healthcare providers are increasingly embracing theranostic approaches, which pair diagnostic imaging with targeted radionuclide therapy to tailor treatment based on individual disease biology. These forces collectively push the field beyond niche academic centers toward routine clinical use across diverse settings, prompting demand for technologies that simplify workflows, ensure quantitative consistency, and support decentralized care delivery.
Turning Convergence into Clinical Reality
GE HealthCare’s strategy focuses on translating scientific convergence into tangible clinical benefits. By aligning imaging hardware, AI‑powered software, and radiopharmaceuticals, the company seeks to reduce barriers that have historically limited nuclear medicine adoption—such as complex image processing, lengthy scan times, and limited tracer availability. The overarching goal is to create a seamless pipeline from detection through therapy planning and monitoring, enabling clinicians to make more informed decisions earlier in the patient journey. This approach is illustrated through specific initiatives in cardiology, neurology, and oncology, each designed to address unique clinical challenges while reinforcing a common theme of scalability and quantitative rigor.
Cardiology Innovations
In cardiology, GE HealthCare is leveraging its Flyrcado (flurpiridaz F 18 injection) to expand access to PET myocardial perfusion imaging (MPI). Flyrcado’s ready‑to‑use, unit‑dose formulation simplifies preparation and integrates smoothly into routine clinical workflows, making high‑quality PET MPI feasible outside traditional hospital nuclear medicine labs. Collaborations with channel partners aim to accelerate adoption in community hospitals and outpatient clinics, while mobile imaging models further extend reach to underserved populations. By lowering logistical and technical hurdles, Flyrcado supports timely detection of myocardial ischemia and infarction, ultimately guiding better revascularization decisions for patients with known or suspected coronary artery disease.
Neurology Advances
The neurology segment addresses the growing demand for Alzheimer’s disease diagnostics. GE HealthCare offers Vizamyl (flutemetamol F 18 injection), a PET radiopharmaceutical that quantifies amyloid beta neuritic plaque density, aiding in the differential diagnosis of cognitive impairment. Complementing Vizamyl, the MIMneuro software suite provides quantitative tools that standardize amyloid PET interpretation, reducing reader variability and facilitating integration into everyday neurological workflows. Together, these technologies enable clinicians to identify suitable candidates for amyloid‑directed therapies earlier, monitor treatment response, and improve overall management of neurodegenerative conditions.
Oncology Theranostics
Oncology represents a rapidly expanding arena for theranostics, where diagnostic imaging directly informs targeted radionuclide therapy. GE HealthCare’s StarGuide SPECT/CT platform—equipped with 12 CZT detectors—delivers high‑quality 3D imaging with short scan times and robust quantitation, essential for accurate tumor burden assessment. The Intelligent Radiation Therapy (iRT) solution and the MIM portfolio further streamline workflows by automating lesion segmentation, physiologic uptake correction, and multi‑image registration, thereby accelerating access to quantitative insights. These capabilities underpin GE HealthCare’s vision of Adaptive Theranostics, a data‑driven framework that links molecular imaging, quantitative analysis, and multidisciplinary collaboration to personalize radioligand therapy across treatment cycles.
Adaptive Theranostics Vision
Adaptive Theranostics embodies GE HealthCare’s commitment to moving beyond static diagnosis toward dynamic, patient‑specific care. By continuously integrating imaging data, quantitative biomarkers, and clinical input, the model supports iterative therapy adjustments that reflect evolving disease biology. This approach promises to enhance treatment efficacy, minimize unnecessary exposure, and foster confidence among clinicians navigating complex theranostic regimens. As adoption scales, the ecosystem surrounding Adaptive Theranostics—including standardized protocols, interoperable software, and trained multidisciplinary teams—will become critical to achieving consistent outcomes across institutions.
Real‑World Clinical Impact at SNMMI 2026
At the SNMMI meeting, GE HealthCare will highlight several technologies that exemplify its commitment to scalable, quantitative nuclear medicine.
Advanced Imaging Technologies
- MIM KineticID: A 510(k)-pending software platform for dynamic PET imaging and kinetic modeling, enabling time‑based analysis of tracer behavior to support nuanced clinical and research decisions.
- MIM LesionID Pro: Recently cleared by the U.S. FDA, this AI‑powered tool automates whole‑body tumor burden analysis, eliminating manual lesion segmentation and physiologic uptake removal while delivering rapid quantitative outputs.
- Omni Legend PET/CT: With over 500 installations worldwide, this high‑sensitivity platform offers up to a 53 % reduction in scan time versus prior generations, improved image quality, and a 16‑20 % gain in small lesion detectability, augmented by Precision DL deep‑learning image reconstruction.
- StarGuide SPECT/CT: A digital system featuring 12 CZT detectors, optimized for theranostic procedures, providing rapid, quantifiable 3D imaging.
- MINItrace Magnix: A compact cyclotron under development that promises on‑site production of PET tracers such as Gallium‑68, thereby expanding radiopharmaceutical access and enabling personalized tracer delivery close to the point of care.
Radiopharmaceuticals and Agents
- Flyrcado: PET MPI agent for evaluating myocardial ischemia and infarction during stress testing.
- DaTscan (ioflupane I‑123 injection): Established tracer for visualizing striatal dopamine transporters in Parkinsonian syndromes and dementia with Lewy bodies.
- Cerianna (fluoroestradiol F 18 injection): PET agent to detect estrogen receptor‑positive lesions in recurrent or metastatic breast cancer, adjunctive to biopsy.
- Vizamyl: PET imaging agent for estimating amyloid beta plaque burden, supporting Alzheimer’s disease work‑up and patient selection for amyloid‑targeted therapies.
These imaging platforms and radiopharmaceuticals collectively aim to foster more scalable, data‑driven, and personalized nuclear medicine workflows across the continuum of care.
Preparing the Next Decade: Infrastructure and Ecosystem
Looking forward, GE HealthCare emphasizes that success in scaling nuclear medicine hinges not only on individual products but on constructing a robust end‑to‑end ecosystem. This ecosystem encompasses tracer development and manufacturing, distribution logistics, workflow integration, and decision‑support tools that enable confident, consistent interpretation. Quantification and advanced imaging analytics are poised to play an increasingly pivotal role, especially in neurodegenerative disease and theranostics, where longitudinal assessment and standardized reporting can reduce inter‑site variability. By promoting workflow standardization, expanding radiopharmaceutical access through localized production solutions like MINItrace Magnix, and delivering AI‑enhanced software that reduces manual burden, GE HealthCare seeks to empower health systems to deliver precision nuclear medicine as a routine, everyday practice rather than an exceptional service.
Conclusion
The 2026 SNMMI annual meeting will serve as a showcase for GE HealthCare’s comprehensive vision: to harness cutting‑edge imaging, AI‑driven analytics, and innovative radiopharmaceuticals to make nuclear medicine more accessible, efficient, and clinically impactful. Through initiatives spanning cardiology, neurology, oncology, and the overarching Adaptive Theranostics framework, the company aims to address the operational challenges that accompany market growth while enabling personalized, quantitative care across diverse settings. As the nuclear medicine market hurtles toward a projected $30.7 billion valuation by 2034, GE HealthCare’s focus on ecosystem building and workflow simplification positions it to help transform scientific promise into sustained, real‑world patient benefit.
